Full history for every metric is available with a Kvantra account
Oncorus, Inc. (ONCR)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -77 | -88 | |||||
| Net profit | $m | - | -18 | -30 | -47 | -65 | -78 | -94 |
| EPS reported | $ | -3.02 | -3.63 | |||||
| Operating cashflow per share | $ | -2.38 | -2.38 | |||||
| Capex per share | $ | 0.77 | 0.77 | |||||
| FCF per share | $ | -3.15 | -3.15 | |||||
| Free cash flow | $m | -82 | -74 | |||||
| Net debt | $m | 43 | -24 | |||||
| Book value equity | $m | 61 | 31 | |||||
| Book value per share | $ | 2.33 | 1.19 | |||||
| Number of shares | m | 25.92 | 26.1 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.11 | 0.11 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.08 | -0.04 | |||||
| EV/EBITDA LTM | x | -0.69 | 0.21 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -1192.5% | -2397.3% | |||||
| FCF Yield | % | -1243.0% | -2245.6% | |||||
| Quality | ||||||||
| ROE | % | -129.38% | -82.19% | |||||
| ROIC | % | -59.36% | -59.36% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.19 | -1.07 | |||||
| Net Debt/EBITDA | x | -0.59 | -0.59 | |||||
| EBIT/Net interest | x | -38.15 | -38.15 | |||||
| Net debt/market cap | % | 650.42% | -743.44% | |||||
| Net debt/Equity | x | 0.71 | -0.79 | |||||
| Gross debt/equity | x | 1.13 | 2.23 | |||||
Company overview
Oncorus, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering viral immunotherapies designed to combat cancer in patients. At the forefront of its pipeline is ONCR-177, an innovative viral immunotherapy that leverages a modified herpes simplex virus type 1 (oHSV-1) platform. This candidate, administered directly into tumors, is presently undergoing Phase I clinical evaluation for a range of different cancers. Beyond this, Oncorus is advancing ONCR-GBM, an oHSV program in preclinical development targeting brain cancer via intratumoral injection. Further research includes synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. In a significant collaboration, Oncorus has partnered with MSD International GmbH (Merck) through a clinical trial and supply agreement. This partnership aims to assess the safety and tolerability of ONCR-177 when administered in combination with Merck's well-known cancer immunotherapy, KEYTRUDA, during a Phase I clinical trial involving patients with solid tumors. Established in 2015, Oncorus, Inc. maintains its headquarters in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Oncorus, Inc. (ONCR)
Oncorus, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering viral immunotherapies designed to combat cancer in patients. At the forefront of its pipeline is ONCR-177, an innovative viral immunotherapy that leverages a modified herpes simplex virus type 1 (oHSV-1) platform. This candidate, administered directly into tumors, is presently undergoing Phase I clinical evaluation for a range of different cancers. Beyond this, Oncorus is advancing ONCR-GBM, an oHSV program in preclinical development targeting brain cancer via intratumoral injection. Further research includes synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. In a significant collaboration, Oncorus has partnered with MSD International GmbH (Merck) through a clinical trial and supply agreement. This partnership aims to assess the safety and tolerability of ONCR-177 when administered in combination with Merck's well-known cancer immunotherapy, KEYTRUDA, during a Phase I clinical trial involving patients with solid tumors. Established in 2015, Oncorus, Inc. maintains its headquarters in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free